Ropes & Gray represented the buyer group consortium of TPG Growth and ShangPharma’s CEO, Michael Xin Hui, ShangPharma’s going private transaction, which closed March 27.
ShangPharma is a leading, China-based contract research organization.
The transaction is just the second private equity sponsor-backed going-private transaction of a China-based, NYSE or NASDAQ listed company to sign and close since the beginning of 2012.
ShangPharma is a leading, China-based contract research organization.
The transaction is just the second private equity sponsor-backed going-private transaction of a China-based, NYSE or NASDAQ listed company to sign and close since the beginning of 2012.
Stay Up To Date with Ropes & Gray
Subscribe to Our Podcast
Ropes & Gray attorneys provide timely analysis on legal developments, court decisions and changes in legislation and regulations.
Follow Us on Social
Stay in the loop with all things Ropes & Gray, and find our more about our people, culture, initiatives and everything that’s happening.
Join Our Mailing List
We regularly notify our clients and contacts of significant legal developments, news, webinars and teleconferences that affect their industries.